FiercePharmaPolitics—COVID-19 brings divisions on hydroxychloroquine, reopening esagonowsky Mon, 05/18/2020 – 10:15

Teva bails on price-fixing settlement in gamble on its role fighting COVID-19: report kblankenship Mon, 05/18/2020 – 10:25

Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer aliu Mon, 05/18/2020 […]

More threat to Gilead’s HIV business? GlaxoSmithKline touts long-acting injectable PrEP win against Truvada aliu Mon, 05/18/2020 – […]

For the past 70 years, the best indicator of life expectancy for a patient with glioblastoma (GBM) has […]

Researchers at the University of Eastern Finland have developed a new and promising drug compound for the treatment […]

“Healthcare staff should work together with patients and carers to educate the next generation of doctors, we’re on […]

The move comes as Oxford Uni and AZ sign a global licensing deal for their vaccine candidate

The drug is being developed for metastatic non-small cell lung cancer (NSCLC) in patients whose tumours have an […]

ViiV said cabotegravir was found to be 69% more effective at preventing HIV acquisition than daily oral PrEP […]